Victory Capital Management Inc. Boosts Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Victory Capital Management Inc. lifted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 52.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,948 shares of the biotechnology company's stock after purchasing an additional 38,002 shares during the period. Victory Capital Management Inc.'s holdings in ADMA Biologics were worth $1,886,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in ADMA. Charles Schwab Investment Management Inc. increased its holdings in ADMA Biologics by 1.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,440,294 shares of the biotechnology company's stock worth $41,851,000 after buying an additional 38,761 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $141,000. Jones Financial Companies Lllp increased its stake in shares of ADMA Biologics by 303.4% during the 4th quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company's stock worth $98,000 after purchasing an additional 4,312 shares during the last quarter. Mutual of America Capital Management LLC raised its holdings in shares of ADMA Biologics by 2.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock worth $614,000 after purchasing an additional 751 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its stake in ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after purchasing an additional 700 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Remove Ads

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA traded up $0.15 during midday trading on Friday, hitting $19.80. The company's stock had a trading volume of 8,289,962 shares, compared to its average volume of 2,647,404. The stock has a fifty day moving average price of $16.74 and a 200 day moving average price of $18.01. The firm has a market capitalization of $4.68 billion, a price-to-earnings ratio of 70.71 and a beta of 0.60. ADMA Biologics, Inc. has a one year low of $5.89 and a one year high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.